A detailed history of Efg Asset Management (North America) Corp. transactions in Veracyte, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 204,254 shares of VCYT stock, worth $8.35 Million. This represents 1.19% of its overall portfolio holdings.

Number of Shares
204,254
Previous 243,878 16.25%
Holding current value
$8.35 Million
Previous $5.28 Million 31.53%
% of portfolio
1.19%
Previous 0.93%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$21.0 - $35.25 $832,104 - $1.4 Million
-39,624 Reduced 16.25%
204,254 $6.95 Million
Q2 2024

Jul 25, 2024

SELL
$18.86 - $23.55 $254,798 - $318,160
-13,510 Reduced 5.25%
243,878 $5.28 Million
Q1 2024

May 13, 2024

BUY
$21.0 - $29.1 $582,708 - $807,466
27,748 Added 12.08%
257,388 $5.7 Million
Q4 2023

Feb 08, 2024

SELL
$19.72 - $28.68 $3,884 - $5,649
-197 Reduced 0.09%
229,640 $6.32 Million
Q3 2023

Nov 02, 2023

SELL
$22.33 - $29.92 $398,702 - $534,221
-17,855 Reduced 7.21%
229,837 $5.13 Million
Q2 2023

Jul 28, 2023

SELL
$20.96 - $26.99 $483,756 - $622,929
-23,080 Reduced 8.52%
247,692 $6.31 Million
Q1 2023

Apr 27, 2023

SELL
$20.58 - $27.89 $423,042 - $573,306
-20,556 Reduced 7.06%
270,772 $6.04 Million
Q4 2022

Feb 03, 2023

SELL
$15.31 - $29.94 $79,688 - $155,837
-5,205 Reduced 1.76%
291,328 $6.91 Million
Q3 2022

Oct 28, 2022

SELL
$16.58 - $27.9 $113,125 - $190,361
-6,823 Reduced 2.25%
296,533 $4.93 Million
Q2 2022

Aug 04, 2022

BUY
$15.45 - $29.52 $187,763 - $358,756
12,153 Added 4.17%
303,356 $6.04 Million
Q1 2022

Apr 26, 2022

BUY
$21.94 - $42.51 $632,376 - $1.23 Million
28,823 Added 10.99%
291,203 $8.03 Million
Q4 2021

Feb 18, 2022

BUY
$36.09 - $53.79 $9.47 Million - $14.1 Million
262,380 New
262,380 $10.8 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.93B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.